TL;DR
The original GHRH peptide. Approved. Withdrawn. Compounded back into clinics.
What is it? A 29-amino-acid peptide — literally the active first third of your own GHRH. Serono got it through the FDA as Geref in 1997 for pediatric growth-hormone deficiency.
What does it do? Hits the same pituitary GHRH receptor your hypothalamus uses every night. Your own pulsatile GH pattern stays intact. No flat injected-hGH plateau, no shutdown of the somatostatin brake.
Does the evidence hold up? Yes, historically. Pediatric registration trials (Thorner 1996), elderly GH-axis restoration (Corpas 1992), cognitive signal in MCI (Baker 2012). The 2008 withdrawal was commercial — the FDA confirmed it had nothing to do with safety.
Who uses it? 503A compounding pharmacies prescribe it for adult off-label GH-axis support. Mostly displaced by CJC-1295 in modern practice.
Bottom line? Cleanest safety record in the GHRH-analog category. Older. Quieter. Still legitimate.
What It Is
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 29 residues of endogenous human growth hormone-releasing hormone (GHRH) — the shortest fragment that retains full biological activity of the 44-amino-acid native molecule. It was developed by Serono Laboratories (later EMD Serono) under the brand name Geref and approved by the US FDA in 1997 for both therapeutic use in pediatric growth hormone deficiency (SubQ daily injection) and as a diagnostic provocative agent (IV single dose) for evaluating pituitary GH reserve.
In December 2008, EMD Serono discontinued both formulations of Geref for commercial reasons. The FDA subsequently confirmed in its 2013 Federal Register notice that the withdrawal was not for safety or effectiveness reasons — Geref was pulled from the market because the pediatric GHD market had shifted decisively to recombinant human growth hormone (somatropin) and the commercial case for continuing to manufacture a GHRH analog no longer closed. That distinction matters: sermorelin has a clean regulatory safety record.
Because the FDA withdrawal was commercial rather than safety-driven, sermorelin remained legally compoundable by 503A and 503B pharmacies under traditional compounding law. This is the single reason sermorelin has remained a mainstay of US physician-prescribed "anti-aging" and wellness-clinic growth-hormone-axis protocols despite not being an approved pharmaceutical product. It is currently prescribed off-label for adult GH insufficiency, age-related decline in GH/IGF-1, and as part of body-composition and sleep-quality protocols in functional-medicine contexts. Unlike BPC-157 or MK-677, sermorelin sits in a unique regulatory space as a formerly-approved, now-compounded peptide drug.
Mechanistically, sermorelin is the archetypal GHRH analog — it binds the GHRH receptor on anterior pituitary somatotrophs and stimulates physiologic, pulsatile GH release. It does not elevate GH to supraphysiologic levels the way exogenous recombinant hGH does. The effect is to restore youthful GH pulse amplitude while preserving the natural pulsatile architecture, including the nocturnal GH surge during slow-wave sleep. That mechanism — "restoring function rather than overriding it" — is the core selling point for sermorelin versus recombinant hGH.
Mechanism of Action
Sermorelin's mechanism is tightly defined. It is a direct GHRH receptor agonist with pharmacology essentially identical to endogenous GHRH.
- GHRH-R agonism (primary) — Sermorelin binds the GHRH receptor (GHRHR), a Gs-coupled GPCR expressed predominantly on pituitary somatotrophs. Activation stimulates adenylate cyclase → cAMP → PKA → calcium signaling → pulsed GH release.
- Preserved pulsatility — Because sermorelin has a short plasma half-life (~10–12 minutes) and acts at the same receptor as endogenous GHRH, it supports the natural pulsatile GH architecture rather than generating a sustained supraphysiologic GH level. Pulsatility matters because chronically elevated flat GH (as with exogenous hGH overdosing) downregulates tissue response and disrupts feedback regulation.
- Somatostatin regulation preserved — Sermorelin does not override pituitary somatostatin tone. If native somatostatin is high (for any reason), sermorelin's effect is blunted. This is a built-in safety feature — the hypothalamus retains ultimate control over GH output.
- Downstream IGF-1 elevation — Restored/amplified GH pulses drive hepatic IGF-1 synthesis. Clinical data show modest IGF-1 elevation typically into the mid-to-upper age-adjusted normal range, not beyond.
- Sleep-architecture support — The nocturnal GH pulse coincides with slow-wave sleep. Sermorelin dosed at bedtime amplifies this natural pulse. Subjective sleep quality improvements are commonly reported and consistent with the mechanism.
- Feedback integrity — Because sermorelin works through the native receptor and preserves pulsatility, long-term use does not appear to downregulate the axis. This contrasts with recombinant hGH, which can suppress endogenous pulsatile GH release through classical negative feedback.
- No direct tissue effects — Sermorelin acts only on the pituitary. It has no known direct action on muscle, adipose, bone, or connective tissue; all downstream effects are mediated by pituitary GH release and subsequent IGF-1 elevation.
- Rapid pharmacokinetics — Peak plasma within 5–10 minutes of SubQ injection; cleared within ~30 minutes. Action is pulse-like rather than sustained, which is why nightly dosing at bedtime aligns with physiology.
What the Research Shows
Sermorelin has one of the more mature clinical-data profiles of any peptide discussed in the community, precisely because it achieved full FDA approval for pediatric GHD before being commercially discontinued.
- Pediatric growth (Thorner et al., JCEM 1996; PMID 8772599) — Geref International Study Group; once-daily SubQ sermorelin accelerated growth velocity in prepubertal children with idiopathic GHD. Growth effects smaller than with recombinant hGH but meaningful in a subset of responders.
- Pediatric GHD first-year therapy (Duck et al., JCEM 1992; PMID 1400880) — Documented safety and growth-velocity improvement in SC GHRH therapy for GH-deficient children.
- Foundational GHRH pulsatile physiology (Vance et al., J Clin Invest 1985; PMID 2860118) — Continuous GHRH infusion confirmed intermittent somatostatin secretion architecture, providing the pulsatility rationale for short-half-life GHRH analogs.
- Elderly GH restoration (Corpas et al., JCEM 1992; PMID 1379256) — GHRH(1-29) twice daily reversed decreased GH and IGF-1 levels in old men.
- Elderly physiologic GHRH administration (Khorram et al., JCEM 1997; PMID 9141535) — Endocrine and metabolic effects of long-term GHRH-(1-29)-NH2 in older men and women.
- GHRH cognition trial (Baker et al., Arch Neurol 2012; PMID 22869065) — 20-week GHRH administration in adults with mild cognitive impairment and healthy older adults showed improvements in executive function and working memory.
- GHRH defect in GH deficiency (Grossman et al., Lancet 1983; PMID 6134966) — Foundational work demonstrating that GH deficiency reflects a hypothalamic defect in GHRH release.
- Adult review (Walker, Clin Interv Aging 2006; PMC2699646) — Review article positioning sermorelin as an alternative approach to adult-onset GH insufficiency. Framework widely adopted in functional-medicine prescribing.
- Diagnostic provocative testing (Ghigo et al., Eur J Endocrinol 1996; PMID 8616536) — Sermorelin 1 μg/kg IV as a provocative agent for pituitary GH reserve.
- Modern functional-medicine data — Post-2008 compounded sermorelin has accumulated a large clinical-experience base in US wellness-clinic prescribing. Formal controlled-trial evidence for adult anti-aging indications remains limited.
Honest Evidence Framing
Sermorelin's pediatric GHD evidence base is rigorous, which is why it achieved FDA approval. Its adult anti-aging use case — dominant in community and wellness-clinic practice — rests on extrapolation and open-label/observational data, not on randomized adult-anti-aging trials. The effect size for adult body composition and sleep is real but modest compared to recombinant hGH, tesamorelin, or MK-677.
Human Data
Sermorelin has more human data than nearly any other peptide in the community space because it reached FDA approval.
- Pediatric GHD — registrational dataset — Randomized and open-label trials in children with idiopathic GHD supporting 1997 FDA approval.
- Geref Diagnostic (0.05 mg ampoule) — IV provocative testing for adult and pediatric GH reserve.
- Adult open-label case series — Smaller observational data on adult body composition, sleep quality, and IGF-1 normalization.
- Elderly GH restoration studies (Corpas 1992, Khorram 1997) — Short-duration physiologic studies confirming restoration of youthful GH pulse patterns.
- Cognitive function (Baker 2012) — 20-week GHRH in older adults showed executive function improvements.
- Wellness-clinic cohorts (post-2008) — Large aggregated experience of compounded sermorelin prescribing in adult anti-aging/functional-medicine practice.
Absent from the human dataset: a large Phase 3 trial specifically for adult anti-aging or age-related body-composition endpoints. This is the gap between the adult-use case and the formal regulatory-grade evidence.
Dosing from the Literature
Dosing below reflects the original Geref label (pediatric GHD and diagnostic) and compounded-pharmacy protocols for adult off-label use.
| Protocol | Dose | Frequency | Notes |
|---|
| Pediatric GHD (original Geref label) | 30 μg/kg | SubQ nightly at bedtime | Approved dose; continued daily. |
| Provocative GH test (Geref Diagnostic) | 1 μg/kg | Single IV dose | Peak GH measurement at 15–30 min post-infusion. |
| Adult anti-aging (community/compounded) | 200–500 μg | SubQ nightly at bedtime | Most common adult dose range. Dosed on empty stomach, near bedtime, to align with natural pulse. |
| Adult split dose | 100–250 μg ×2 | Morning + bedtime | Some clinicians add a second morning dose for training/recovery purposes. |
| Cycle length | 3–6 months on | — | Break of 1 month every 6 months is common but not required. No tachyphylaxis documented. |
Dosing Disclaimer
The 200–500 μg adult dose is compounded-pharmacy practice, not an FDA-labeled adult dose. Doses below 100 μg have minimal GH-pulse effect; doses above 500 μg show diminishing returns. Individual sensitivity varies. Working with a licensed physician prescribing compounded sermorelin is the proper route.
Reconstitution & Storage
Sermorelin acetate is supplied as a lyophilized powder from compounding pharmacies. Vial sizes typically range from 2 mg to 15 mg.
| Vial Size | BAC Water | Concentration | 200 μg Dose | 500 μg Dose |
|---|
| 2 mg | 1 mL | 2 mg/mL | 10 units (0.10 mL) | 25 units (0.25 mL) |
| 5 mg | 2 mL | 2.5 mg/mL | 8 units (0.08 mL) | 20 units (0.20 mL) |
| 5 mg | 1 mL | 5 mg/mL | 4 units (0.04 mL) | 10 units (0.10 mL) |
| 15 mg | 3 mL | 5 mg/mL | 4 units (0.04 mL) | 10 units (0.10 mL) |
- Reconstitution — Inject BAC water slowly down the vial wall at 45°. Swirl; do not shake. Solution should be clear and colorless.
- Storage — Unreconstituted: 2–8°C strictly preferred. Reconstituted: 2–8°C, use within 14–21 days. Sermorelin is less stable in solution than many peptides.
- Injection site — SubQ in abdomen (2" from navel), thigh, or upper arm. Rotate sites.
- Timing — At bedtime, ≥2 hours after last meal. Empty stomach preserves GH pulse.
- Inspection — Discard if cloudy, discolored, or has particulates.
→ Use the Kalios Peptide Calculator for exact syringe units
Side Effects & Risks
Important
The Geref-era trials documented mostly mild local reactions and a clean systemic profile. Long-term adult use is less rigorously studied. Worth discussing with your doctor before starting a chronic course.
Sermorelin has one of the cleanest safety profiles of any GH-axis compound. Original Geref clinical trials documented mostly mild, local adverse events.
- Injection site reactions — Most common AE. Mild erythema, local pain, occasional bruising. Typically self-limited.
- Flushing / warmth — Transient facial flushing or warmth within minutes of injection; uncommon, self-limited.
- Headache — Mild, occasional.
- Dizziness / orthostasis — Rare, mild, usually resolves with continued dosing.
- Altered taste sensation — Reported in some users, usually transient.
- GI upset — Mild nausea or discomfort; rare.
- Hyperactivity / restlessness — Rare; typically in first few doses.
- Water retention — Mild, transient, much less than MK-677.
- No documented cardiovascular signal — Unlike MK-677, sermorelin has no flagged cardiovascular signal in the original registrational database.
- Insulin sensitivity — Minimal impact at physiologic doses. Chronic high-dose use elevates IGF-1 and can modestly affect glucose metabolism; much less than MK-677.
- Cancer / IGF-1 concerns — Because sermorelin elevates GH/IGF-1, general GH-axis cancer cautions apply: avoid in active malignancy or in users with strong cancer risk profile (particularly IGF-1-sensitive cancers like breast, prostate, colorectal).
- WADA banned — As a named GHRH analog, sermorelin is banned under S2. Athletes subject to anti-doping testing cannot use.
- Drug interactions — Thyroid hormones and corticosteroids can alter sermorelin response. Insulin and oral hypoglycemics may need minor adjustment at high sustained doses.
- Purity (compounded pharmacy) — Use a licensed, audited compounding pharmacy with documented cGMP. Sermorelin is legitimately available compounded in the US; no need to source gray-market research chemical.
Bloodwork & Monitoring
Sensible monitoring for adult off-label sermorelin use:
- IGF-1 (baseline and at 4, 12 weeks) — Primary biomarker. Target age-adjusted mid-to-upper normal range. Persistent IGF-1 above age-adjusted normal is a stop signal.
- IGFBP-3 — Complementary marker for GH-axis function. Useful if IGF-1 is borderline.
- Baseline CMP — Liver, kidney, glucose. Repeat at 12 weeks.
- HbA1c + fasting glucose — Baseline and periodic. Small changes at physiologic dose; watch at higher chronic dose.
- Thyroid (TSH, free T4) — Baseline. GH-axis changes can unmask subclinical thyroid issues.
- Cortisol (morning) — Baseline if clinically indicated.
- PSA / mammography / age-appropriate cancer screen — Standard age-appropriate screening before extended use.
- Body composition (DEXA) — Baseline and at 6 months for objective tracking if body-composition is a goal endpoint.
- Sleep tracking — Wearable or clinical polysomnography if sleep quality is a primary endpoint.
Commonly Stacked With
The most common sermorelin pairing. Different receptor (GHSR-1a vs GHRH-R) with synergistic GH-pulse effect. Standard "GHRH + GHRP" stack in wellness-clinic practice — usually dosed together at bedtime. Produces larger GH pulse than either alone without meaningful cortisol/prolactin elevation.
Modified GHRH analog with modest half-life extension over native GHRH/sermorelin but without the ultra-long DAC-modified variant's steady-state pharmacokinetics. Some clinicians prescribe CJC-1295 (no DAC) as a sermorelin alternative; the "with DAC" version trades pulsatility for duration.
Pairs well for tissue repair + growth-axis support. BPC-157's local VEGFR2/NO/FAK mechanism is independent of GH-axis signaling. Combined in injury recovery protocols.
Men on TRT commonly add sermorelin or sermorelin + ipamorelin for a fuller anabolic axis — testosterone for androgen restoration, GH-axis support for body composition and recovery. Requires clinician oversight and monitoring of all three axes.
Occasionally substituted or rotated with sermorelin. Tesamorelin has a stabilized structure, longer half-life, and more aggressive visceral fat effect. Not typically stacked with sermorelin (same mechanism).
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
Sermorelin acetate was FDA-approved (brand Geref) in 1997 for pediatric growth hormone deficiency (treatment) and for diagnostic evaluation of pituitary GH reserve. In 2008, EMD Serono discontinued commercial production for commercial reasons. The FDA confirmed in its 2013 Federal Register notice that the withdrawal was not for reasons of safety or effectiveness.
Because the withdrawal was commercial and safety/efficacy were preserved, sermorelin is legally compoundable by 503A and 503B pharmacies under a valid prescription. It is the most-prescribed GHRH-analog peptide in US wellness-clinic practice as a result. This is a meaningful distinction from BPC-157, TB-500, or MK-677, which are on the FDA Category 2 list and cannot be legally compounded.
Sermorelin is banned by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics) of the Prohibited List as a named GHRH analog. Athletes subject to anti-doping testing cannot use sermorelin under any circumstance.
The 2026 HHS Category 2 reclassification announcement does not affect sermorelin, which was never on the Category 2 list.
Cost & Access
Sermorelin acetate is available through licensed compounding pharmacies where legally permitted for clinician-prescribed off-label use through 503A pharmacies. It is widely dispensed via the men's health, TRT/HRT, and longevity clinic ecosystem, often as part of growth hormone secretagogue protocols (frequently combined with ipamorelin or GHRP-2).
Sermorelin acetate was previously FDA-approved as Geref (Serono / EMD Serono) for pediatric growth hormone deficiency diagnosis; Geref was voluntarily discontinued by the manufacturer in 2008 for commercial reasons (low sales volume), not safety. Sermorelin has remained available through the licensed compounding pharmacy pathway since.
Sermorelin's status under HHS Secretary Robert F. Kennedy Jr.'s February 2026 reclassification announcement is unchanged because it has not been on the Category 2 list — it is already eligible for compounding pharmacy use under the standard 503A pathway as a previously-FDA-approved active ingredient. The RFK reclassification framework specifically addresses Category 2 peptides historically restricted from compounding, which does not include sermorelin.
Estimated pricing as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
People researching sermorelin often also look at these:
CJC-1295 + ipamorelin — the classic GHRH + GHRP combination for natural growth-hormone pulse amplification.
Ibutamoren — oral nonpeptide ghrelin-receptor agonist producing 24-hour GH/IGF-1 elevation.
Recombinant human growth hormone (somatropin). 191-amino-acid protein used for GH deficiency and off-label performance.
Key References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID: 18031173.
- Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908. PMC2699646.
- Vance ML, Kaiser DL, Evans WS, et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor. Evidence for intermittent somatostatin secretion. J Clin Invest. 1985;75(5):1584-1590. PMID: 2860118.
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in older men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141535.
- Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. PMID: 22869065.
- Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 1996;134(3):352-356. PMID: 8616536.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PMID: 1379256.
- Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-1196. PMID: 8772599.
- Duck SC, Schwarz HP, Costin G, et al. Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. J Clin Endocrinol Metab. 1992;75(4):1115-1120. PMID: 1400880.
- Grossman A, Savage MO, Wass JA, Lytras N, Sueiras-Diaz J, Coy DH, Besser GM. Growth-hormone-releasing factor in growth hormone deficiency: demonstration of a hypothalamic defect in growth hormone release. Lancet. 1983;2(8343):137-138. PMID: 6134966.
- Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14662999.
- US Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection ... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Fed Regist. 2013;78(43):14124.
- Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37.
- WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency.
- American Association of Clinical Endocrinologists. Clinical Practice Guidelines for Growth Hormone Use in Growth Hormone-Deficient Adults and Transition Patients — 2019 Update.
Last updated: April 2026 | Profile authored by Kalios Peptides research team